The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Risk of Nephrolithiasis in Cirrhosis: A Comparison between MASLD Cirrhosis and Cirrhosis Due to Other Etiologies

Authors: Sarpong Boateng, MD, MPH, Mayssaa Hoteit, MD, Prince Ameyaw, MD, Simran Joshi, MD, Alexa Plato, MD, Rofina Johnkennedy, MD, MPH, Donghyun Ko, MD, MS, Abhiraj Patel, MD, Frances Mejia, MD, Cheng-Hung Tai, MD, Basile Njei, MD, MPH, PhD, Gregory Buller, MD

Abstract

Objectives: Nephrolithiasis is a systemic condition influenced by metabolic disorders, with rising prevalence worldwide. Although several studies have investigated the relationship between metabolic-associated steatotic liver disease (MASLD) and nephrolithiasis, few have focused on cirrhosis-specific etiologies. As the epidemiology of cirrhosis shifts from viral and alcohol-related causes to metabolic dysfunction-related etiologies, understanding how these different causes influence the risk of nephrolithiasis is crucial. This study aims to evaluate the association between MASLD cirrhosis and nephrolithiasis, compared with other cirrhosis etiologies, using a nationally representative cohort.

Methods: We conducted a retrospective cohort study using the US National Inpatient Sample from 2016 to 2020. Patients aged 18 years and older with a diagnosis of cirrhosis were included. Cirrhosis etiologies were categorized as MASLD cirrhosis and non-MASLD cirrhosis (including alcohol, chronic viral hepatitis, and other causes). The primary outcome was attaining a diagnosis of nephrolithiasis. Propensity score matching was performed to balance covariates between groups. Multivariate logistic regression models were used to estimate adjusted odds ratios (aORs) for nephrolithiasis risk, accounting for demographics, comorbidities and hospital characteristics. Sensitivity analysis using the E-value was conducted to assess robustness of the findings.

Results: In total, 112,312 patients with cirrhosis were included after matching; 56,156 patients were classified with MASLD cirrhosis and 56,156 with non-MASLD cirrhosis. The mean age of patients in the matched cohort was 64.2 ± 11.48 years, with 39.5% being male. Patients with MASLD cirrhosis were less likely to have Medicaid (12.0% vs 17.5%) (P < 0.0001) or to be from lower-income households (31.8% vs 35.3%) compared with those with cirrhosis of other etiologies (P < 0.0001). In multivariate analysis, MASLD cirrhosis was associated with a significantly higher risk of nephrolithiasis compared with non-MASLD cirrhosis (aOR 1.229, 95% confidence interval [CI] 1.093–1.383, P < 0.0001). Subgroup analysis revealed that the risk of nephrolithiasis was significantly higher in MASLD cirrhosis compared with alcohol-related cirrhosis (aOR 1.328, 95% CI 1.053–1.692, P = 0.020), and to other cirrhosis types (aOR 1.147, 95% CI 1.010–1.305, P = 0.035), but not significantly different from viral hepatitis-related cirrhosis (aOR 1.124, 95% CI 0.894–1.429, P = 0.33). Sensitivity analysis using the E-value indicated that an unmeasured confounder would need to have an odds ratio of at least 1.76 to explain for the observed association.

Conclusions: MASLD cirrhosis is associated with a higher risk of nephrolithiasis than cirrhosis of other etiologies. Our findings underscore the need for tailored nephrolithiasis screening and management strategies for patients with MASLD cirrhosis, particularly as the burden of metabolic-related liver disease continues to rise.
Posted in: Liver Disease10

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020;16(12):736–746.
 
2. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021;49(1):27–39.
 
3. Roberson D, Sperling C, Shah A, et al. Economic Considerations in the Management of Nephrolithiasis. Curr Urol Rep. 2020;21(5):18.
 
4. Pearle MS, Calhoun EA, Curhan GC, Urologic Diseases of America P. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848–57.
 
5. Saigal CS, Joyce G, Timilsina AR, Urologic Diseases in America P. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int. 2005;68(4):1808–14.
 
6. Shastri S, Patel J, Sambandam KK, et al. Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. Am J Kidney Dis. 2023;82(5):617–634.
 
7. Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388–398.
 
8. Henin G, Loumaye A, Leclercq IA, et al. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2024;6(2): 100963.
 
9. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.
 
10. Hagstrom H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76–e77.
 
11. Younossi ZM, Paik JM, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80(5):694–701.
 
12. Liu M, Gao M, Wu J, et al. Metabolic Syndrome and the Risk of Kidney Stones: a Large-scale Cohort Study from 487,860 UK Biobank participants. J Clin Endocrinol Metab. 2024; dgae295.
 
13. Ye Z, Wu C, Xiong Y, et al. Obesity, metabolic dysfunction, and risk of kidney stone disease: a national cross-sectional study. Aging Male. 2023;26(1):2195932.
 
14. Decker RD, Ghiraldi EM, Weiss AH, et al. Nonalcoholic Fatty Liver Disease Is an Independent Risk Factor for Nephrolithiasis in Women: Findings from NHANES III. J Endourol. 2020;34(12):1258–1262.
 
15. Mantovani A, Morandin R, Fiorio V, et al. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis. Intern Emerg Med. 2024; 1745–1755.
 
16. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 2006;74(5):767–76.
 
17. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open. 2020;3(4):e201997.
 
18. Taguchi K, Okada A, Unno R, et al. Macrophage Function in Calcium Oxalate Kidney Stone Formation: A Systematic Review of Literature. Front Immunol. 2021;12:673690.
 
19. Sanchez PS, Rigual MDM, Djouder N. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers (Basel). 2021;13(20) .
 
20. Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–S42.
 
21. Wadhwa V, Jobanputra Y, Garg SK, et al. Nationwide trends of hospital admissions for acute cholecystitis in the United States. Gastroenterol Rep (Oxf ) 2017;5(1):36–42.
 
22. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288–94.
 
23. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268–274.
 
24. Qin S, Wang S, Wang X, et al. Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(35):e12092.
 
25. Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open. 2021;12:100149.
 
26. Abate N, Chandalia M, Cabo-Chan AV et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65(2):386–92.
 
27. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455–62.
 
28. Lemann J, Jr., Piering WF, Lennon EJ. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med. 1969;280(5):232–7.
 
29. Eisner BH, Eisenberg ML, Stoller ML. Relationship between body mass index and quantitative 24-hour urine chemistries in patients with nephrolithiasis. Urology. 2010;75(6):1289–93.
 
30. Powell CR, Stoller ML, Schwartz BF, et al. Impact of body weight on urinary electrolytes in urinary stone formers. Urology. 2000;55(6):825–30.
 
31. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114(4):764–74.
 
32. Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999–1007.
 
33. Khan SR, Glenton PA, Backov R, et al. Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney Int. 2002;62(6):2062–72.
 
34. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol. 2014;3(3):256–276.